



## **Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures**

October 16, 2023

Call scheduled for Tuesday, October 17, 2023 at 8:00 a.m. ET

SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that it will host a conference call on Tuesday, October 17, 2023 at 8:00 a.m. ET to discuss clinical program updates and organizational cost measures and resource prioritization to support clinical milestones.

### **Conference Call and Webcast**

To access the conference call, please register through this link: <https://nkarta-business-update.open-exchange.net/registration>

A replay will be archived on the Investors section of Nkarta's website, [www.nkartatx.com](http://www.nkartatx.com), for approximately four weeks.

### **About Nkarta**

Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company's website at [www.nkartatx.com](http://www.nkartatx.com).

### **Nkarta Media/Investor Contact:**

Greg Mann  
Nkarta, Inc.  
[gmann@nkartatx.com](mailto:gmann@nkartatx.com)